Epitalon
Also known as: Ala-Glu-Asp-Gly · Epithalon · Epitalone
A short synthetic tetrapeptide developed in the Khavinson bioregulator programme, studied for telomere maintenance, pineal regulation, and indirect cognitive effects via circadian and stress-resilience pathways.
Epitalon is a Khavinson tetrapeptide (Ala-Glu-Asp-Gly) studied for pineal-directed and telomerase-inducing gerontoprotective effects across multi-decade Russian cohorts.
Evidence tier: B — clinical evidence (trials or approved use in some jurisdictions)
- Category
- Neuroprotection
- Half-life
- Short plasma half-life; gene-expression effects persist beyond clearance
- Formula
- C₁₄H₂₂N₄O₉
- Weight
- 390.35 g/mol
- Sequence
- Ala-Glu-Asp-Gly
Section 1
Overview
Epitalon is a synthetic four-amino-acid peptide developed in the same St. Petersburg Institute of Bioregulation and Gerontology programme that produced Pinealon, Cerluten, and Thymalin. The conceptual heritage is Vladimir Khavinson's hypothesis that very short peptides can pass through the cell and nuclear membranes and act as direct gene-expression regulators by binding specific DNA motifs.
The molecule is positioned in the Khavinson framework as a pineal-targeted bioregulator. Its most-cited research findings concern modulation of melatonin rhythms, induction of telomerase activity in cultured cells, and extension of average and maximum lifespan in rodent studies. The cognitive relevance — the reason it appears on a nootropic-peptide reference — is indirect: circadian regulation and stress-resilience modulation feed back into next-day cognitive performance, and ageing-related cognitive decline is one of the endpoints the broader programme targets.
Outside the Khavinson group and collaborators, independent replication of the most distinctive claims — particularly the direct DNA-binding mechanism — has been limited. The phenotypic effects on telomerase activity in cell culture are well-documented; the molecular details of how a tetrapeptide reaches and binds chromatin are more contested.
Section 2
Discovery & History
- Synthesised in the 1990s at the St. Petersburg Institute of Bioregulation and Gerontology under the direction of Vladimir Khavinson, as the synthetic equivalent of pineal-gland peptide extracts that the institute had been studying since the 1980s.
- Subject to a substantial body of Russian peer-reviewed work covering telomerase induction, melatonin-rhythm restoration, retinal-protection effects, and gerontoprotective outcomes in rodent models.
- Studied in human research primarily in Russia in elderly populations, with reports of improved sleep architecture, immune-function markers, and subjective wellbeing on cyclical administration protocols.
- Remains a research chemical in all Western jurisdictions, including the United Kingdom.
Section 3
Mechanism of Action
- 1Proposed direct binding to specific DNA promoter sequences in pineal-relevant genes, modulating transcription of melatonin-synthesis enzymes (arylalkylamine N-acetyltransferase) and other circadian effectors — the central Khavinson-school mechanism, biophysically characterised by the originating group.
- 2Induction of telomerase activity in cultured human somatic cells with corresponding extension of replicative lifespan and reduction of senescence markers — the cellular signature most cited in Western secondary literature and the most-replicated Khavinson-programme finding.
- 3Restoration of melatonin-rhythm amplitude in aged animal models with otherwise blunted circadian melatonin production, providing a phenotypic biomarker of the proposed pineal-directed transcriptional effect.
- 4Antioxidant effects in retinal and CNS tissue, particularly under age-related oxidative stress — measurable reductions in lipid peroxidation markers and preserved endogenous antioxidant enzyme activity.
- 5Indirect downstream cognitive effects through circadian regulation and stress-axis attenuation — the route by which a pineal-acting peptide reaches cognitive endpoints, and the mechanism-of-action angle that positions Epitalon on a nootropic-peptide reference.
- 6Modulation of neuroendocrine ageing markers — reported effects on the gonadotropin, growth hormone, and cortisol axes in aged cohorts consistent with the broader gerontoprotective framework.
- 7Preservation of retinal function in aged and stress-perturbed models, with an approved Russian clinical indication in age-related retinal degeneration research.
Section 4
Researched Benefits
Findings reported in the published preclinical and clinical literature. Effects in research contexts do not constitute claims of therapeutic benefit in humans.
- 1Reported telomerase induction and extension of replicative lifespan in cultured cells — the flagship cellular-mechanism finding.
- 2Restoration of melatonin-rhythm amplitude in aged animal models, with corresponding improvements in circadian consolidation and sleep-wake regulation.
- 3Improvements in subjective sleep quality and wellbeing in Russian elderly-population research, particularly in subjects with age-related melatonin-rhythm blunting.
- 4Antioxidant and retinal-protective effects in oxidative-stress models — extending the neuroprotective evidence base into age-related retinal degeneration research.
- 5Used as a research tool for studying pineal-gland regulation and circadian-cognition relationships in cognitive-ageing research designs.
- 6Part of the broader gerontoprotective programme alongside Pinealon and other Khavinson bioregulators, with multi-decade Russian cohort data reporting reductions in age-related morbidity and mortality.
- 7Reported neuroendocrine normalisation in aged cohorts, particularly on the gonadotropin and cortisol axes.
Section 5
Theoretical Dosing & Protocols
| Route | Dosage | Frequency | Duration |
|---|---|---|---|
| Subcutaneous / intranasal (research) | Microgram-range doses in animal and clinical-research protocols | Typically once daily during a course | Cyclical protocols of 10–20 days, repeated periodically rather than continuous |
Note: No standardised Western clinical protocol exists. Russian research practice uses cycles rather than continuous administration.
Section 6
Administration Routes
- Subcutaneous injection — the primary route in animal research and Russian clinical practice; the reference administration modality for the peptide's characterised pharmacology.
- Intranasal administration is documented in some protocols and provides an alternative to injection where practicality is a consideration.
- Intramuscular administration is used in some Russian clinical protocols where subcutaneous access is impractical.
- Oral administration is not viable — the tetrapeptide is degraded by gastrointestinal proteases and undergoes near-complete first-pass metabolism.
Section 7
Safety Profile
Commonly reported
- · Generally well-tolerated in published animal and Russian clinical research at studied doses — the Khavinson bioregulator peptides collectively display unusually clean acute-tolerability profiles.
- · Mild local irritation at the injection site occasionally reported, typically self-limiting.
- · Occasional mild sleepiness in the first few days of a course, consistent with the melatonin-modulating mechanism.
- · Well-tolerated across the Russian elderly-population research cohorts, with adverse-event rates comparable to placebo.
Rare / theoretical
- · Long-term safety data outside the Khavinson group is limited; independent Western replication of the multi-decade cohort work has not been performed.
- · The direct DNA-binding mechanism (if it occurs as proposed) raises theoretical concerns about off-target gene regulation that have not been comprehensively investigated outside the originating research programme.
- · Telomerase induction is itself a process implicated in some oncogenic pathways; whether the magnitude produced by Epitalon administration carries meaningful tumour-risk implications is uncharacterised in long-term human research.
- · Theoretical interaction with circadian-active medications (melatonin agonists/antagonists, sleep-promoting agents) given the shared pineal-endpoint mechanism.
Contraindications
- · Not authorised for human use in the UK, EU (centralised), or US — supply for human consumption is prohibited under the Human Medicines Regulations 2012 in the UK.
- · Pregnancy and lactation — no controlled human data.
- · Active or historic malignancy — theoretical contraindication via the telomerase-induction mechanism.
- · Severe pineal-region pathology (pineal tumours, pinealectomy status) — the pineal-directed mechanism is not characterised in these baselines.
Section 8
UK & EU Regulatory Context
United Kingdom
Not licensed as a medicine in the United Kingdom. Research chemical only.
European Union
Not approved by the EMA. Used in research and traditional clinical practice in the Russian Federation as part of the bioregulator family.
Section 9
Clinical Studies Summary
Epitalon and telomerase activity in cultured human somatic cells
Khavinson-group publications reporting dose-dependent induction of telomerase activity in human fibroblast cultures, with corresponding extension of replicative capacity beyond the Hayflick limit and reduction of senescence markers. The most-cited cellular-level finding for Epitalon and the mechanism-of-action root for the broader gerontoprotective claims.
Read studyPineal peptide effects on melatonin rhythm in aged animals
Chronobiology study demonstrating restoration of melatonin amplitude and circadian-rhythm regularity in aged rodent models receiving cyclical Epitalon administration versus age-matched controls, providing the phenotypic biomarker link between the proposed pineal-directed transcriptional mechanism and a measurable circadian output.
Read studyGerontoprotective effect of Epitalon in long-term rodent studies
Multi-year lifespan study reporting extension of both average and maximum lifespan in mouse and rat populations receiving lifelong Epitalon administration versus vehicle controls; the effect was attributed to combined circadian, antioxidant, and telomerase-related mechanisms operating in concert rather than any single pathway.
Epitalon in age-related retinal degeneration
Clinical research in elderly cohorts with age-related retinal degeneration reporting preserved retinal function and improved subjective visual outcomes over a 10-day intranasal Epitalon course, extending the neuroprotective evidence base into ocular tissue.
Epitalon 10-year cohort mortality data
Long-term Khavinson-group cohort study following elderly research subjects on cyclical Epitalon protocols over a decade, reporting reduced age-related morbidity and mortality relative to demographic-matched controls in the same regional cohort. The flagship human-cohort finding for the Epitalon gerontoprotective programme.
Section 10
Frequently Asked Questions
Section 10a
Practical Research Guidance
Cycle guidance
Reconstitution & storage
UK sourcing notes
Section 11
Sourcing for Laboratory Research
Sourcing Epitalon for laboratory research
Researchers in the United Kingdom and elsewhere typically obtain Epitalon from specialist research-chemical suppliers. Purity, third-party testing, and supplier transparency are the principal differentiators worth evaluating before placing an order. The two suppliers below are commonly referenced in UK research contexts.
Reminder: research peptides are sold strictly for in vitro and preclinical laboratory purposes. Importation or supply for human consumption is not permitted under UK medicines legislation.